CS-0159 is under clinical development by Cascade Pharmaceuticals and currently in Phase I for Primary Sclerosing Cholangitis. According to GlobalData, Phase I drugs for Primary Sclerosing Cholangitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CS-0159 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CS-0159 is under development for the treatment of primary sclerosing cholangitis, nonalcoholic steatohepatitis (NASH), inflammatory bowel disease and primary biliary cholangitis. It is administered through oral route. It acts by targeting farnesoid X receptor (FXR).
Cascade Pharmaceuticals overview
Cascade Pharmaceuticals is a pharmaceutical research and development enterprise that focusing on the early discovery, drug development and subsequent commercialization of innovative drugs for nuclear receptors. The company is headquartered in Shanghai, China.
For a complete picture of CS-0159’s drug-specific PTSR and LoA scores, buy the report here.